药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)
apolipoprotein E-deficient (apoE−/− ) mouse model, 326–327, 326f 326
atrial fibrillation (AF) normal sinus rhythm, 327, 327f 327
pacing model, 328–329, 329f 329
sterile pericarditis dog model, 328,328f 328
cholesterol, 325–326, 325f 325
hypercholesterolemia, diet-induced 0
characteristics and impact, 421–422 422
diagnostic biomarkers, 420–421 421
DPP-IV inhibitors (Januvia®), 432–434,433f 433
FDG PET imaging agent, 436–437 437
imaging agents and technologies 0
[18F] fluororasagiline, 428–429, 429f 429
[18F] fluororeboxetine, 429, 429f 429
functional magnetic resonance 0
human chorionic gonadotropin (hCG),424 424
L-829,165-18F, 438f, 439 165-18, 438, 439
magnetic resonance imaging (MRI),430–431 431
neurokinin 1 (NK1), 438–439 439
non-specific binding, 429–430 430
positron emission tomography (PET),426–427, 427t 427
selective orexin receptor antagonists,436 436
single-photon emission computed 0
Electrophysiological patch clamp, 191–193,192f–193f 193
Elixir of Sulfanilamide disaster, 69–71, 69f 69
Endocytosis, 255, 255f 255